Wall Street analysts expect Curis, Inc. (NASDAQ:CRIS) to report earnings per share of ($0.09) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Curis’ earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.11). Curis also reported earnings of ($0.09) per share in the same quarter last year. The business is expected to announce its next earnings results on Thursday, August 3rd.

On average, analysts expect that Curis will report full-year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.34). For the next financial year, analysts expect that the business will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.52) to ($0.21). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Curis.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. The firm had revenue of $2.13 million during the quarter, compared to the consensus estimate of $1.98 million. Curis had a negative net margin of 841.05% and a negative return on equity of 163.29%. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) earnings per share.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Curis in a research report on Monday, May 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $5.88.

In other Curis news, Director James R. Mcnab sold 116,708 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $2.38, for a total value of $277,765.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James R. Mcnab sold 146,694 shares of the company’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $2.61, for a total transaction of $382,871.34. Following the completion of the transaction, the director now directly owns 912,426 shares in the company, valued at approximately $2,381,431.86. The disclosure for this sale can be found here. Insiders sold 339,678 shares of company stock worth $816,239 in the last ninety days. 4.07% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Curis during the first quarter worth about $105,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Curis by 22.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after buying an additional 7,638 shares during the period. Two Sigma Investments LP acquired a new stake in shares of Curis during the fourth quarter worth about $183,000. Finally, American International Group Inc. raised its stake in shares of Curis by 7.1% in the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after buying an additional 4,560 shares during the period. Institutional investors own 51.68% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 EPS” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/26/zacks-brokerages-anticipate-curis-inc-cris-to-announce-0-09-eps.html.

Curis (NASDAQ CRIS) traded up 1.46% during mid-day trading on Wednesday, hitting $2.08. 69,282 shares of the stock traded hands. The company’s market cap is $299.05 million. The company’s 50 day moving average is $1.94 and its 200 day moving average is $2.37. Curis has a 12 month low of $1.57 and a 12 month high of $3.72.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.